- Home
- RARE
as 11-21-2024 10:38am EST
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | NOVATO |
| Market Cap: | 5.2B | IPO Year: | 2014 |
| Target Price: | $86.79 | AVG Volume (30 days): | 947.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.43 | EPS Growth: | N/A |
| 52 Week Low/High: | $37.02 - $60.37 | Next Earning Date: | 11-05-2024 |
| Revenue: | $522,745,000 | Revenue Growth: | 27.44% |
| Revenue Growth (this year): | 27.29% | Revenue Growth (next year): | 18.30% |
Stock Insider Trading Activity of Ultragenyx Pharmaceutical Inc. (RARE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Horn Howard | RARE | Chief Financial Officer | Oct 10 '24 | Sell | $52.76 | 7,465 | $393,853.40 | 92,301 | |
| Huizenga Theodore Alan | RARE | SVP, Chief Accounting Officer | Sep 3 '24 | Sell | $56.19 | 91 | $5,113.29 | 41,551 | |
| KAKKIS EMIL D | RARE | President & CEO | Sep 3 '24 | Sell | $55.85 | 20,000 | $1,117,000.00 | 2,223,985 |
Latest Ultragenyx Pharmaceutical Inc. News
RARE Breaking Stock News: Dive into RARE Ticker-Specific Updates for Smart Investing
GlobeNewswire
19 hours ago
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
12 days ago
Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit
Simply Wall St.
14 days ago
Ultragenyx Pharmaceutical Third Quarter 2024 Earnings: Beats Expectations
Zacks
15 days ago
Ultragenyx Q3 Loss Narrower Than Expected, Revenues Beat Estimates
GuruFocus.com
15 days ago
Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings Call Highlights: Robust Revenue Growth ...
MT Newswires
16 days ago
Ultragenyx Pharmaceutical Q3 Net Loss Narrows, Revenue Rises; Shares Fall After Hours
Associated Press Finance
16 days ago
Ultragenyx: Q3 Earnings Snapshot
GlobeNewswire
16 days ago
Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
Compare RARE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RARE Ultragenyx Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.